CAMBRIDGE, Mass. — The Centers for Disease Control and Prevention has awarded Abt Associates two new contracts to evaluate the effectiveness of the H1N1 vaccine among health care workers and children younger than 18, the company announced March 5.
In December the CDC awarded the company a related contract to evaluate the vaccine's effectiveness among pregnant women.
The CDC considers all three groups high-risk populations either because of increased risk for complications or because of increased risk of contracting or spreading the disease.
The combined value of these contracts total $12.8 million.
As with the original contract, Abt Associates will prepare detailed protocols for the studies, identify and enroll study participants, coordinate testing of participants for infection with influenza viruses, develop and maintain all study databases and assist the CDC with data analysis.
Abt Associates, an employee-owned company, applies scientific research, technical assistance, survey and consulting expertise to a wide range of social, economic and health policy issues; international development; clinical trials and registries; and complex business problems.